Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06727305 · ClinicalTrials.gov registry record · Phase 1
MTOR Inhibitors in Older Adults
A Phase 1 study of Aging, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06727305 is a Phase 1 study of Aging that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 60 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06727305, a Phase 1 study of Aging, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Over the past decades, healthcare systems face significant challenges to meet the needs of an aging population due to progressive debility, functional decline and chronic diseases development. While there is a growing appreciation of the potential impact of mTOR inhibitors on slowing aging processes, preventing chronic disease and prolonging healthy lifespan, a major challenge in developing clinical trials to establish the clinical efficacy of mTOR inhibitors is the absence of pharmacokinetics (PK) and pharmacodynamics (PD) data in older adults. The proposed study will provide the foundation for future clinical trials assessing the role of mTOR inhibitors on aging related indications
Conditions Studied
Interventions
- DRUG Sirolimus 0.5 Mg Oral Tablet
- DRUG Sirolimus 1Mg Oral Tablet
- DRUG Sirolimus 2 MG Oral Tablet
- DRUG Everolimus 0.5 MG Oral Tablet
- DRUG Everolimus 1 MG Oral Tablet
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-02 |
| Est. Completion | 2027-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06727305
The ClinicalTrials.gov registry entry for NCT06727305 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (97% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Aging appearing as the primary indexed condition, and to 5 interventions - of which Sirolimus 0.5 Mg Oral Tablet is the first listed.
NCT06727305 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06727305 about?
NCT06727305 is a clinical study titled "MTOR Inhibitors in Older Adults". Over the past decades, healthcare systems face significant challenges to meet the needs of an aging population due to progressive debility, functional decline and chronic diseases development. While there is a growing appreciation of the potential impact of mTOR inhibitors on slowing aging processes...
What is the current status of trial NCT06727305?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2026-02. Estimated completion is 2027-11-13.
What conditions does trial NCT06727305 study?
This clinical trial studies the following conditions: Aging.
What interventions are being tested in trial NCT06727305?
The interventions under investigation include: Sirolimus 0.5 Mg Oral Tablet (DRUG), Sirolimus 1Mg Oral Tablet (DRUG), Sirolimus 2 MG Oral Tablet (DRUG), Everolimus 0.5 MG Oral Tablet (DRUG), Everolimus 1 MG Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT06727305?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06727305 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of a Daily Supplement on Plasma PAI-1 Levels
RECRUITING · Phase 1
-
Rapalog Pharmacology (RAP PAC) Study
RECRUITING · Phase 1
-
Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults
RECRUITING · Phase 1
-
Fisetin to Improve Vascular Function in Older Adults
ACTIVE NOT RECRUITING · Phase 1
-
Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women
ACTIVE NOT RECRUITING · Phase 1
-
Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.